Clinical trials: Empagliflozin
Hypertension
Short Term Effect of Empagliflozin in Hypertension
The investigators assessed the 6-week effect of once daily 25mg SGLT2-i Empagliflozin on left ventricular diastolic function and blood pressure profile in non diabetic hypertensive patients
- Trial name
- EMPHYT (NCT04203914)
- Testing
- Empagliflozin Tablets
- Where
- 2 sites in Cameroon
- Volunteers
- 15 people
- Sponsor
- Yaounde Central Hospital
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
The purpose of the study is to demonstrate the superiority of sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on a DPP4(i) with or…
- Trial name
- SOTA-EMPA (NCT03351478)
- Testing
- Sotagliflozin, Empagliflozin
- Where
- 160 sites in United States, Bulgaria and 10 more
- Volunteers
- 770 people
- Sponsor
- Lexicon Pharmaceuticals
Glycogen Storage Disease Type IB
Efficacy and Safety of Empagliflozin in GSD-Ib Patients
Empagliflozin Treatment of GSD-1b patients
- Trial name
- NCT05960617
- Testing
- Empagliflozin
- Where
- China
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Diabetes Mellitus Type 2
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Empagliflozin and metformin hydrochloride are two separate drugs. The combination of these two drugs in one tablet are used for the treatment of type 2 diabetes, along with diet and exercise, and can be used with other drugs, if…
- Trial name
- NCT06792968
- Testing
- Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets, Synjardy 5 mg/1000 mg film-coated tablets
- Where
- Russia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Gedeon Richter Plc.
Type 2 Diabetes, Microvascular Coronary Artery Disease
Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)
The study design is a double blinded randomised control trial study that aims to conduct a randomised controlled trial of empagliflozin and determine if empagliflozin will improve myocardial blood flow in asymptomatic high risk…
- Trial name
- CATCH-EM (NCT04541797)
- Testing
- Empagliflozin 10 MG, Stress Cardiac Magnetic Resonance
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Healthy
A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the safety and pharmacokinetics after co-administration of CTL0201 and CTL0202 or administration of CT-L02 in healthy volunteers.
- Trial name
- NCT07128654
- Testing
- CTL02, CTL0201, CTL0202
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Celltrion
Healthy
Empa/Lina FDC Food Effect Study (Japan)
The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet.
- Trial name
- NCT02815644
- Testing
- empagliflozin/linagliptin FDC
- Where
- Japan
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
This open-label study aims to evaluate the impact of BI 10773 treatment on glomerular filtration rate under controlled conditions of euglycaemia and hyperglycaemia in subjects with type 1 diabetes mellitus with or without renal…
- Trial name
- NCT01392560
- Testing
- BI 10773
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes, NAFLD
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Non-Alcoholic Fatty Liver Disease( NAFLD) is common in patients with type 2 diabetes. Empagliflozin, an FDA-approved oral medication used to treat type 2 diabetes, has been shown to reduce production and deposition of fat in the…
- Trial name
- NCT02964715
- Testing
- Empagliflozin
- Where
- Malaysia
- Volunteers
- 25 people
- Sponsor
- University of Malaya
Obesity, Heart Failure
The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
The aim of this trial is to assess the effect of Empagliflozin on lipid and glucose metabolism as well as volume homeostasis and renal function in elderly and obese patients with increased risk of developing heart failure.
- Trial name
- NCT05042973
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Denmark
- Volunteers
- 165 people
- Sponsor
- Jacob Moller
Kidney Transplant; Complications
Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation
The purpose of this study is to investigate the effect of empagliflozin on oxidative stress in patients with type 2 diabetes after kidney transplantation.
- Trial name
- NCT04918407
- Testing
- Empagliflozin 25 MG, Insulin
- Where
- 2 sites in Iran
- Volunteers
- 40 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Kidney Disease, Chronic
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice.
- Trial name
- NCT06287073
- Testing
- JARDIANCE®
- Where
- 12 sites in South Korea
- Volunteers
- 299 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, two way crossover, Oral Bioequivalence Study of test product of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet and…
- Trial name
- NCT07266766
- Testing
- Empagliflozin / Metformin HCl XR Tablets, Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Humanis Saglık Anonim Sirketi
Healthy
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
The purpose of this trial is to investigate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combination of empagliflozin and…
- Trial name
- NCT02266472
- Testing
- metformin, empagliflozin/metformin, empagliflozin
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ischemic Cardiomyopathy
RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy
To compare the effects of physiology- and imaging-guided PCI combined with optimal medical therapy (OMT) versus OMT alone on the recovery of left ventricular systolic function in patients with ischemic cardiomyopathy and…
- Trial name
- IMPROVE-ICMP (NCT06930092)
- Testing
- Physiology-and imaging-guided PCI, Optimal medical treatment
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Seoul National University Hospital
Obstructive Sleep Apnea (OSA), Sleep Apnea Syndrome, Obstructive
Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.
The goal of this randomized clinical trial was to evaluate the effects of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i) on sleep and cardiac outcomes in adults with heart failure (HF) and obstructive sleep…
- Conditions
- Obstructive Sleep Apnea (OSA), Sleep Apnea Syndrome, Obstructive, Heart Failure
- Trial name
- HF(L)OSA (NCT07556094)
- Testing
- Empagliflozin, Continuous Positive Airway Pressure (CPAP)
- Where
- Poland
- Volunteers
- 70 people
- Sponsor
- Medical University of Bialystok
Partial Islet Function, TPIAT
SGLT2i Therapy in Islet Transplantation (SIT)
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who…
- Conditions
- Partial Islet Function, TPIAT, Diabetes
- Trial name
- NCT07228195
- Testing
- Empagliflozin 25 MG Oral Tablet, Empagliflozin 10 MG Oral Tablet [Jardiance]
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Heart Failure, Diabetes Mellitus
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
Empagliflozin treatment in high cardiovascular risk patients has been shown to have a relatively rapid powerful capability in reducing cardiovascular mortality.
- Conditions
- Heart Failure, Diabetes Mellitus, Arrythmia
- Trial name
- ERA-HF (NCT03271879)
- Testing
- Empagliflozin at a dose of 10 mg/day
- Volunteers
- 128 people
- Sponsor
- Rambam Health Care Campus
Type 2 Diabetes, Fatty Liver
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty…
- Trial name
- NCT06989723
- Testing
- Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Bundang Hospital
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 304 (NCT05504239)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Handok Inc.